BIOMERIEUX
See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo
16165_1442005_PR_bioMrieux_SPOTFIRE_VG_Panel_FDA_Clearance_20261022.pdf
bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Filed with Euronext ·
Watch bioMerieux's latest callBiomerieux (Euronext:BIM) Q2 2026 Earnings Call · Replay · Jul 28Read the transcript of Biomerieux (Euronext:BIM) Q2 2026 Earnings Call6ix is reading this filing.
View original source (Euronext)bioMerieux SA on 6ix
Earlier from bioMerieux
- WHO Grants Emergency Use Listing for BIOFIRE Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response
- Septembre 2026 - Déclaration sur le nombre d\'actions composant le capital social et sur le nombre de droits de vote correspondant
- bioMerieux: BioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
- bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026
- BioMérieux – First-Half 2026 Results
Follow bioMerieux into a list and get an email when it puts out news.
Follow bioMerieux